Nevertheless, it has been noted that thyroid cancers with BRAF pathogenic variants tend to respond less favorably to redifferentiation therapies, suggesting that a stronger inhibition of the MAPK pathway may be necessary, potentially through a dual therapy of BRAF and MEK inhibitors. Here, BRAF is linked to thyroid cancer.